Year : 2014 | Volume
: 59 | Issue : 5 | Page : 469--472
Ethical use of topical corticosteroids
Indushree Skin Clinic, Lucknow, Uttar Pradesh, India
Indushree Skin Clinic, B 7, Indira Nagar, Lucknow 226 016, Uttar Pradesh
Dermatologists rely very heavily on corticosteroids for treating many common dermatoses. Concerns about their incorrect use are widely expressed both in lay public and specialist discourse. From the point of view of medical ethics, issues of autonomy, beneficence and non-maleficence are all raised frequently when we prescribe topical corticosteroids to our patients. We need to be aware of situations when conflicts between these issues arise and have a clear thought process about resolving them. This can only be achieved if we have a thorough understanding of the skin disease being treated coupled with expertise in the use of the varied potencies and available dosage forms of topical corticosteroids. A good understanding of human psychology and effective communication is also needed to use these agents optimally.
|How to cite this article:|
Saraswat A. Ethical use of topical corticosteroids.Indian J Dermatol 2014;59:469-472
|How to cite this URL:|
Saraswat A. Ethical use of topical corticosteroids. Indian J Dermatol [serial online] 2014 [cited 2021 Mar 8 ];59:469-472
Available from: https://www.e-ijd.org/text.asp?2014/59/5/469/139877
Topical corticosteroids (TC) are probably the most important therapeutic agents in dermatology. They have antipruritic, anti-inflammatory, anti-proliferative and pigment-lightening activity on the skin.  This wide-ranging activity profile leads to their frequent use in dermatology prescriptions. A recent prescription audit from a dermatology OPD revealed that close to 30% of all prescriptions contained a TC.  An important reason for such widespread use is their ability to produce rapid alleviation of unpleasant signs and symptoms on the skin. Symptoms such as itch, stinging and tenderness are rapidly relieved regardless of the cause, as are redness, scaling and hyperpigmentation. Unfortunately, this "improvement" may be short-lived and can be followed by worsening of the original condition if TCs are not used correctly or used in conditions where they are not indicated at all.
The natural instinct of every physician is to give rapid relief to a patient who is distressed and TCs are ideally suited for such a role. However, this instinct needs to be tempered with caution. This is because TCs are highly susceptible to misuse by patients, pharmacists and physicians themselves as several studies have shown. ,, If not properly counseled, patients may not return for a follow-up and may continue to use the TC for prolonged periods. Such improper use can have devastating consequences, both local and systemic, in the long run.  It is therefore essential that we develop a clear understanding of the ethics of TC prescribing so that they are used optimally for the benefit of our patients.
In our country, easy availability of mild to superpotent TCs even without a prescription coupled with rampant sharing of TCs by patients has created a situation where they seem to be more misused then used correctly. , On the other hand, steroid phobia is becoming increasingly common in the internet-savvy population in the cities creating new problems in prescription of TCs.  In this backdrop, ethical and careful prescription of these powerful agents is the need of the hour.
What are The Ethical Issues That are Relevant to Topical Corticosteroid Use?
Many ethical issues impinge on the physician prescribing TCs to a patient. Awareness of these issues is essential so that pitfalls can be avoided and a good doctor-patient relationship be established. The most important issues are mentioned below.
1. Autonomy: This refers to respect for the individuals' right to make informed decisions about their personal matters. In other words, the patient has the right to refuse or choose their treatment (Voluntas aegroti suprema lex.) This is in contrast to the older paternalistic style of medicine where patients were simply advised on what to take without any discussion of alternatives, risk vs. benefit etc., With regards to TCs, this law applies when we are faced with a steroid-phobic patient. In this situation, "soft paternalism"  is often a good approach whereby such a patient should be counseled about the potential benefits of TC use, the harm that can be caused by non-use and how common adverse effects can be avoided. However, they should also be informed about alternative therapies e.g. topical calcineurin inhibitors or calcipotriol and their efficacy vis-ΰ-vis TCs. After this, whatever their ultimate decision be, it should be respected.
2. Non-maleficence: This is the principle of primum non nocere (first, do no harm). There are important ramifications of this principle in a TC prescription. A common scenario where non-maleficence needs to be remembered is a patient who is obsessed with a fair complexion and asks for a TC prescription which he/she may have heard about from a friend. It is absolutely essential to avoid the temptation to give in to the patient's request in this situation. Non-maleficence also becomes relevant when we are dealing with an undiagnosed rash and a demanding, distressed patient. Several studies have been reported on the misuse of TCs, especially on the face ,, where the initial prescription was given for an undiagnosed facial rash which then led to prolonged misuse of TCs leading to considerable morbidity. In such a scenario, pending a diagnosis, TCs should be avoided and relief given with safer options like topical antipruritics and oral antihistamines. In the absence of a clear diagnosis and treatment plan, a physician should not hesitate to refer a patient to a senior colleague or an expert instead of using TCs to suppress unpleasant symptoms indefinitely.
3. Beneficence vs. autonomy: This kind of conflict occurs when patients disagree with recommendations that doctors believe are in the patients' best interest. An appropriate example would be a patient with widespread eczema who is applying potent TCs over a large area leading to adverse effects.  The appropriate approach in such a situation would be to start a systemic steroid-sparing drug like azathioprine and gradually taper the TC. However, many patients are scared of systemic immunosuppressives and resist such treatment. Appropriate counseling about the dangers of potent TC use over large areas along with laboratory demonstration of adrenal suppression etc., will be needed to convince the patient.
In fact, effective communication is the key to resolving almost all ethical dilemmas faced by a physician prescribing TCs. Not only doctor-patient, but communication between doctors of different specialties and between doctors and society in general is essential in resolving these ethical issues. This is discussed in greater detail in later sections (vide infra).
What are The Parameters of Proper Use of Topical Corticosteroids?
Correct use of TCs is predicated on the fulfilling of the following conditions:
The right diagnosis: There are relatively few conditions where there is good evidence of efficacy of TCs. Various eczemas, psoriasis, lichen planus, immunobullous diseases in their localized form, skin manifestations of collagen vascular diseases like lupus erythematosus or dermatomyositis are the best established indications. Other conditions where careful, short-term use may be warranted are superficial fungal or bacterial infections associated with significant inflammation, localized itch of any origin and certain idiopathic diseases characterized by dermal inflammation e.g. superficial variants of pyoderma gangrenosum. In the absence of a diagnosis, it is very important to avoid TC use so that conditions like tinea incognito and Majocchi's granuloma are not produced.  If a patient is already applying TC thereby obscuring the clinical features of a disease, an appropriate treatment-free interval should be given after explaining to the patient that his/her symptoms may flare up temporarily, to facilitate a diagnosis.The right molecule and delivery system: Since they were first introduced in the early 1950s, TCs have grown tremendously as a class and today, more than 20 different molecules of varying potency are available worldwide, ranging from mild to superpotent. In addition, there are varying concentrations and dosage forms available, namely creams, gels, lotions, ointments, foams, muco-adherent gels, aerosols and tapes. It is important for the prescriber to be familiar with at least a few of the molecules, preferably of differing potencies.  The characteristics of the various dosage forms should also be thoroughly understood so that the correct drug in the correct vehicle can be given in a particular situation. Although it is generally good to err on the side of caution when prescribing TCs, in many situations, it is better to prescribe a more potent molecule to control the disease quickly and stop treatment fast instead of prolonged treatment with a mild formulation. This is especially true of self-limited conditions like acute irritant dermatitis, paederous dermatitis etc.The right patient: The age, sex and occupation of the patient play an important role in determining TC use. Very young and very old patients have impaired epidermal barrier function and relatively thinner skin. In addition, infants have a very high surface area to weight ratio that can lead to disproportionately high systemic absorption from topical application.  Women who do housework often have damaged skin due to frequent wet-dry cycling. This creates the need for more frequent application, as do certain occupations involving manual labor. Other factors like the anatomical location and extent of the disease also dictate which formulation is optimal. Thin skin areas like eyelids, face and scrotum need milder products than back, palms and soles. Widespread dermatoses demand easily spreadable dosage forms and milder potencies to guard against undesirable systemic absorption.  Cosmetic considerations are paramount when TCs are applied on the face or other visible parts and creams, gels and lotions are preferred here due to their elegance. Intertriginous areas are particularly susceptible to stronger than expected effect due to the occlusion and maceration of the skin and therefore we should err on the side of caution when deciding the potency on these sites. The right amount, frequency and duration: Perhaps the commonest omission in a TC prescription is advice regarding the right amount to be applied in a particular situation. In this regard, the Fingertip Unit (FTU) devised by Long and Finlay  is the simplest way to explain to the patient how much TC is to be applied. An FTU is the amount of ointment that occupies the space from the fingertip to the first skin crease when squeezed out of a 5 mm nozzle. This amount was found to be 0.5 g for most adult-sized hands. This amount is enough to cover a palm-sized area on the skin in the case of creams and about 20% more with ointments due to their increased spreadability. Standard recommendations have been developed to guide how many FTUs are required to cover particular anatomical areas.  This should be clearly conveyed to the patient to prevent over- or underuse.
The frequency of application is dependent on patient factors such as site and occupation. Hands and feet often need twice or thrice a day application due to the propensity of being rubbed off. Otherwise, most experts agree that once daily application is optimal for all other sites since more frequent application has shown no added benefit , and adherence is also expected to be higher with this regimen.
The duration of treatment needs to be clearly told to the patient orally as well as in writing and he/she should also be apprised of the dangers of overuse at this point. In general, a follow-up visit should be planned after 2 to 4 weeks to review the progress and institute the exit strategy.The right "exit strategy": It is extremely important to have a clear plan in mind about tapering and stopping TC use after adequate control/remission has been achieved. Except for self-limiting conditions, TC use is often needed for extended periods, much longer than recommended safe durations. This can be done safely by tapering down to progressively less potent preparations or instituting alternate-day or weekends-only treatment.  Emollients and/or steroid-sparing drugs like calcineurin inhibitors are prescribed on TC-free days. Finding the right exit strategy can involve a lot of empiricism but is a worthwhile skill to learn for every physician.Focusing on prevention and modifiable factors: In many conditions, lasting remission or cure is only achievable if preventive actions are taken or behavioral modifications are done. TCs can only give temporary relief in these situations. Recurrent irritant hand dermatitis, pseudofolliculitis barbae and intertrigo are good examples of these conditions. Physicians should ensure that the quick relief provided by TCs does not make them complacent about tackling deeper issues.  They should explain to the patients that relief will be transient if preventive actions like skin protection and moisturizing (hand eczema), changing shaving habits (pseudofolliculitis barbae) and keeping the skin dry, losing weight and wearing loose natural fabrics (intertrigo) are not done.Being aware of corticosteroid allergy: Many times we are faced with a patient who does not show the desired improvement even if appropriate TC is being used. At other times, control is achieved, only to lead to episodes of increased disease activity which are controlled with increasingly higher potency corticosteroids. In these situations, we should be aware of the possibility of contact dermatitis to topical corticosteroids. , This can happen both due to the preservatives/other excipients or the active molecule per se. In these cases, appropriate patch testing followed by prescription of an allergen-free product should be done.Effective communication: Involving and informing the patient at every step of diagnosis and treatment is the key to using TCs safely, ethically and effectively. A few scenarios are presented below to exemplify this point.
Patients often self-treat themselves with over-the-counter TCs before coming to the physician, altering the appearance of the skin and making diagnosis difficult.  In such a situation, it behooves us to explain the situation to the patient and withdraw all TCs while relevant investigations are done. Even if no investigations are done, a steroid-free interval often renders the disease recognizable, allowing proper treatment to be started.
Patients often neglect to come for follow-up when asked to, either due to financial constraints such as loss of wages/inability to pay re-visit fees or simply due to negligence. To minimize the chances of adverse effects of TC, partial control of the treatment should be handed over to the patient, thus making them partners in their well-being, not just the recipients of instructions. To this end, they can be told at which point they should start alternate day treatment, introduce a calcineurin inhibitor or switch over to a milder TC. With this, they should also be told the warning signs of common adverse effects like folliculitis which would necessitate a re-visit immediately.
Many patients are unsure how long it would take for the effect of TCs to start and therefore either become anxious too quickly or continue to use an ineffective TC preparation till the next scheduled visit. To avoid this, patients should be clearly told approximately how long it would take for the beneficial effects of the TC to "kick in". They should be counseled to walk in if they are not feeling substantially better at this point.
Corticosteroid phobia is an increasingly common problem in urban and internet-savvy patients.  A lot of counseling and reassurance is needed if these patients or their dependents are not to be denied the benefits of TCs. They also need to be told about the non-TC options available and their relative efficacy. If they still choose not to use TCs, their choice should be respected and an appropriate regimen devised.
Today, both patients and physicians contribute to the issues associated with rational and ethical use of topical corticosteroids. Patients are prone to misuse them due to their unrestricted availability and poor awareness about their adverse effects. A smaller but growing section of patients is gravitating toward the other extreme, i.e. an unwarranted fear of topical corticosteroids largely driven by an alarmist media. Dermatologists who number about 7000 in our country are grossly insufficient to care for our vast population and are consequently overworked and often lack the time and skills to counsel the patients regarding safe use. Other specialists and general practitioners who probably see more dermatology patients than dermatologists suffer from grossly inadequate dermatology training. Therefore, it is imperative that increased awareness about ethical use of these agents is created amongst all caregivers so that they are used to their fullest extent and with maximum safety for the benefit of humanity.
|1||Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19:101-2.|
|2||Rathod SS, Motghare VM, Deshmukh VS, Deshpande RP, Bhamare CG, Patil JR. Prescribing practices of topical corticosteroids in the outpatient dermatology department of a rural tertiary care teaching hospital. Indian J Dermatol 2013;58:342-5.|
|3||Saraswat A, Lahiri K, Chatterjee M, Barua S, Coondoo A, Mittal A, et al. Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients. Indian J Dermatol Venereol Leprol 2011;77:160-6.|
|4||Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: A clinical study of 110 cases. Indian J Dermatol Venereol Leprol 2011;77:42-6.|
|5||Al-Dhalimi MA, Aljawahiry N. Misuse of topical corticosteroids: A clinical study in an Iraqi hospital. East Mediterr Health J 2006;12:847-52.|
|6||Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for the use of topical glucocorticosteroids. American academy of dermatology. J Am Acad Dermatol 1996;35:615-9.|
|7||Bewley A. Dermatology working group. Expert consensus: Time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 2008;158:917-20.|
|8||Hector C. Nudging towards nutrition? Soft paternalism and obesity related reform. Food Drug Law J 2012;67:103-22, iii-iv.|
|9||Chen AY, Zirwas MJ. Steroid-induced rosacea like dermatitis: Case report and review of the literature. Cutis 2009;83:198-204.|
|10||Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. J Am Acad Dermatol 1998;38:318-21.|
|11||Solomon BA, Glass AT, Rabbin PE. Tinea incognito and "over-the-counter" potent topical steroids. Cutis 1996;58:295-6.|
|12||Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79:135-40.|
|13||Saraswat A. Topical corticosteroid use in children: Adverse effects and how to minimize them. Indian J Dermatol Venereol Leprol 2010;76:225-8.|
|14||Munro DD. The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol 1976;94 Suppl 12:67-76.|
|15||Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995;162:123-6.|
|16||Long CC, Finlay AY. The finger-tip unit-a new practical measure. Clin Exp Dermatol 1991;16:444-7.|
|17||Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 2012;57:251-9.|
|18||Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ 2007;334:1272.|
|19||Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: An overview. Br J Dermatol 1998;139:763-6.|
|20||Giannotti B. Current treatment guidelines for topical corticosteroids. Drugs 1988;36 Supp 5:9-14.|
|21||Saraswat A. Contact allergy to topical corticosteroids and sunscreens. Indian J Dermatol Venereol Leprol 2012;78:552-9.|
|22||Scheuer E, Warshaw E. Allergy to corticosteroids: Update and review of epidemiology, clinical characteristics, and structural cross-reactivity. Am J Contact Dermat 2003;14:179-87.|
|23||Solomon BA, Glass AT, Rabbin PE. Tinea incognito and "over-the-counter" potent topical steroids. Cutis 1996;58:295-6.|